STMN-1 is a potential marker of lymph node metastasis in distal esophageal adenocarcinomas and silencing its expression can reverse malignant phenotype of tumor cells

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Akhtar, Javed ^a   Wang, Zhou ^a   Yu, Che ^a   Li, Chen Sheng ^a   Shi, Yu Long ^a   Liu, Hong Jun ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Distal esophageal adenocarcinoma; Multivariate logistic regression; Short hairpin RNA; Stathmin1

Indexed keywords

SHORT HAIRPIN RNA; STATHMIN; STATHMIN 1; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; DISTAL ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL ADENOCARCINOMA; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR; TUMOR CELL; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ESOPHAGEAL NEOPLASMS; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; LOGISTIC MODELS; LYMPHATIC METASTASIS; MALE; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; PHENOTYPE; RNA INTERFERENCE; STATHMIN; TIME FACTORS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84892408205     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-28     Document Type: Article

References (28)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
3. Kachroo S, Etzel CJ. Decreasing the cancer burden in developing countries: concerns and recommendations. Eur J Cancer Care (Engl) 2009, 18:18-21. 10.1111/j.1365-2354.2008.00985.x, 19473221.
4. Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours 2009, Oxford, UK: Wiley-Blackwell, 7.
5. AJCC Cancer Staging Handbook ftACSM 2010, 129-143. New York, NY: Springer, 7, AJCC Cancer Staging Handbook.
6. Sobel A. Stathmin: a relay phosphoprotein for multiple signal transduction. Trends Biochem Sci 1991, 16:301-305.
7. Rana S, Maples PB, Senzer N, Nemunaitis J. Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther 2008, 8:1461-1470. 10.1586/14737140.8.9.1461, 18759697.
8. Mistry SJ, Li H-C, Atweh GF. Role for protein phosphatases in the cellcycle-regulated phosphorylation of stathmin. Biochem J 1998, 334:23-29. 1219656, 9693097.
9. Singer S, Ehemann V, Brauckhoff A, Keith M, Vreden S, Schirmacher P, Breuhahn K. Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis. Hepatology 2007, 46:759-768. 10.1002/hep.21736, 17663418.
10. Sherbet GV, Cajone F. Stathmin in cell proliferation and cancer progression. Cancer Genomics Proteomics 2005, 2:227-238.
11. Belletti B, Baldassarre G. Stathmin: a protein with many tasks. New biomarker and potential target in cancer. Expert Opin Ther Targets 2011, 15:1249-1266. 10.1517/14728222.2011.620951, 21978024.
12. Mistry S, Atweh G. Role of stathmin in the regulation of the mitotic spindle: potential applications in cancer therapy. Mt Sinai J Med 2002, 69:299-304.
13. Kuo M-F, Wang H-S, Kuo Q-T, Shun C-T, Hsu H-C, Yang S-H, Yuan R-H. High expression of stathmin protein predicts a fulminant course in medulloblastoma. J Neurosurg Pediatr 2009, 4:74-80. 10.3171/2009.2.PEDS08287, 19569914.
14. Kouzu Y, Uzawa K, Koike H, Saito K, Nakashima D, Higo M, Endo Y, Kasamatsu A, Shiiba M, Bukawa H, et al. Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer 2006, 94(5):717-723. 2361217, 16495930.
15. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, Koujak S, Ferrando AA, Malmström P, Memeo L, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A 2007, 2;104:7564-7569.
16. Golouh R, Cufer T, Sadikov A, Nussdorfer P, Usher PA, Brünner N, Schmitt M, Lesche R, Maier S, Timmermans M, et al. The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study. Breast Cancer Res Treat 2008, 110:317-326. 10.1007/s10549-007-9724-3, 17874182.
17. Brattsand G. Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors. Br J Cancer 2000, 83:311-318. 10.1054/bjoc.2000.1264, 2374559, 10917544.
18. Lin WC, Chen SC, Hu FC, Chueh SC, Pu YS, Yu HJ, Huang KH. Expression of stathmin in localized upper urinary tract urothelial carcinoma: correlations with prognosis. Urology 2009, 74:1264-1269. 10.1016/j.urology.2009.04.088, 19800106.
19. Su D, Smith SM, Preti M, Schwartz P, Rutherford TJ, Menato G, Danese S, Ma S, Yu H, Katsaros D. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer 2009, 1;115:2453-2463.
20. Baldassarre G, Belletti B, Nicoloso MS, Schiappacassi M, Vecchione A, Spessotto P, Morrione A, Canzonieri V, Colombatti A. p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 2005, 7:51-63. 10.1016/j.ccr.2004.11.025, 15652749.
21. Iancu-Rubin C, Atweh GF. p27(Kip1) and stathmin share the stage for the first time. Trends Cell Biol 2005, 15:346-348. 10.1016/j.tcb.2005.05.008, 15951178.
22. Adams J, Cory S. The bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26:1324-1337. 10.1038/sj.onc.1210220, 2930981, 17322918.
23. Adams JM. Ways of dying: multiple pathways to apoptosis. Genes Dev 2003, 17:2481-2495. 10.1101/gad.1126903, 14561771.
24. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004, 116:205-219. 10.1016/S0092-8674(04)00046-7, 14744432.
25. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Rev Cancer 2005, 5:876-885.
26. Jeha S, Luo X-N, Beran M, Kantarjian H, Atweh GF. Antisense RNA inhibition of phosphoprotein p18 expression abrogates the transformed phenotype of leukemic cells. Cancer Res 1996, 56:1445-1450.
27. Gewirtz AM. On future's doorstep: RNA interference and the pharmacopeia of tomorrow. J Clin Invest 2007, 117:3612-3614. 10.1172/JCI34274, 2096464, 18060018.
28. Grimm D. Small silencing RNAs: state-of-the-art. Adv Drug Deliv Rev 2009, 61:672-703. 10.1016/j.addr.2009.05.002, 19427885.